MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
Sign Up to like & getrecommendations! Published in 2021 at "Genomics"
DOI: 10.1016/j.ygeno.2021.04.011
Abstract: Infliximab/adalimumab (IFX/ADA) and vedolizumab (VDZ) are the most widely used biologics in inflammatory bowel diseases. Current models used to predict their efficacies are restricted to either Crohn's disease or ulcerative colitis or to only one… read more here.
Keywords: ifx ada; vdz; inflammatory bowel; bowel diseases ... See more keywords
THU0037 Immunogenicity in a tertiary care hospital: our experience
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2800
Abstract: Background The drugs called Anti-TNF inhibitors are capable of inducing an immune response (immunogenicity) Its effectiveness may be affected by the development of Anti-Drug Antibodies (Ab) Objectives To assess the frequency of appearance of Anti-Drug… read more here.
Keywords: drug; ifx ada; anti tnf; ada etn ... See more keywords